The DOI matches its Crossref record; 49 of the 53 references it cites were found in a registry or an index.
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review
Open accessAbstract
Non-alcoholic fatty liver disease is a serious and growing clinical problem. Despite lifestyle modification, i.e. diet and physical activity, being the recommended therapy, there are currently no systematic evaluations of its efficacy. This review applies a systematic approach to evaluating lifestyle modifications studied to date. Medline (Pubmed), Scopus, and the Cochrane Controlled Trials Register were searched for studies and study groups assessing the effect of diet, physical activity, and/or exercise modification in adult populations with non-alcoholic fatty liver disease. The outcome markers of interest were indicators of steatosis, histological evidence of inflammation and fibrosis, and glucose control/insulin sensitivity. We identified 23 studies for inclusion; seven had control groups, but only six were randomised. Eleven groups received diet-only interventions, two exercise-only, and 19 diet and physical activity/exercise. Studies consistently showed reductions in liver fat and/or liver aminotransferase concentration, with the strongest correlation being with weight reduction. Of the 5 studies reporting changes in histopathology, all showed a trend towards reduction in inflammation, in 2 this was statistically significant. Changes in fibrosis were less consistent with only one study showing a significant reduction. The majority of studies also reported improvements in glucose control/insulin sensitivity following intervention. However, study design, definition of disease, assessment methods, and interventions varied considerably across studies. Lifestyle modifications leading to weight reduction and/or increased physical activity consistently reduced liver fat and improved glucose control/insulin sensitivity. Limited data also suggest that lifestyle interventions may hold benefits for histopathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A meta-analysis of lifestyle interventions in people with MASLD identified weight loss of between 4% and14% with a corresponding reduction in liver fat of 4–10%.27”
From Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD (2025) · cites this paper as [27]
Citations
Cites
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications
Fabbrini, E., Sullivan, S., & Klein, S. (2010) · Hepatology · doi:10.1002/hep.23280 · Cited by 2,100
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907
Self-citationSzczepaniak, L. S., Nurenberg, P., Leonard, D. S., Browning, J. D., Reingold, J. S., Grundy, S. M., Hobbs, H. H., & Dobbins, R. L. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00064.2004 · Cited by 1,573
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
MOFRAD, P., Contos, M. J., Haque, M., Sargeant, C., Fisher, R. A., Luketic, V. A., Sterling, R. K., Shiffman, M. L., Stravitz, R. T., & Sanyal, A. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50229 · Cited by 1,199
Petersen, K. F., Dufour, S., Befroy, D., Lehrke, M., Hendler, R. E., & Shulman, G. I. (2005) · Diabetes · doi:10.2337/diabetes.54.3.603 · Cited by 911
Schwenzer, N. F., Springer, F., Schraml, C., Stefan, N., Machann, J., & Schick, F. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.05.023 · Cited by 751
Exercise for type 2 diabetes mellitus
Thomas, D., Elliott, E. J., & Naughton, G. A. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002968.pub2 · Cited by 728
Fracanzani, A. L., Valenti, L. V. C., Bugianesi, E., Andreoletti, M., Colli, A., Vanni, E., Bertelli, C., Fatta, E., Bignamini, D., Marchesini, G., et al. (2008) · Hepatology · doi:10.1002/hep.22429 · Cited by 716
Flagged first, then by citations
4 of the 53 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 523
Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease
Centis, E., Moscatiello, S., Bugianesi, E., Bellentani, S., Fracanzani, A. L., Calugi, S., Petta, S., Grave, R. D., & Marchesini, G. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.11.031 · Cited by 91
Obesity-Associated Nonalcoholic Fatty Liver Disease
Yilmaz, Y. N., & Younossi, Z. M. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.09.018 · Cited by 91
Health Benefits of Long-Term Weight-Loss Maintenance
Rueda‐Clausen, C. F., Ogunleye, A. A., & Sharma, A. M. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034434 · Cited by 93
Effects of physical activity upon the liver
Shephard, R. J., & Johnson, N. A. (2014) · European Journal of Applied Physiology · doi:10.1007/s00421-014-3031-6 · Cited by 93
Emerging Role of Hepatic Ketogenesis in Fatty Liver Disease
Mooli, R. G. R., & Ramakrishnan, S. K. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.946474 · Cited by 92
Silva, H. E. D., Arendt, B. M., Noureldin, S. A., Therapondos, G., Guindi, M. M., & Allard, J. P. (2014) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2014.01.009 · Cited by 86
Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease
Lonardo, A., Ballestri, S., Targher, G., & Loria, P. (2014) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.965143 · Cited by 86
Cantero, I., Abete, I., Babió, N., Arós, F., Corella, D., Estruch, R., Fitó, M., Hébert, J. R., Martínez‐González, M. Á., Pintó, X., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2017.06.027 · Cited by 86
Cantero, I., Abete, I., Monreal, J., Martínez, J. A., & Zulet, M. Á. (2017) · Nutrients · doi:10.3390/nu9070667 · Cited by 83
Wan, J., Zhang, Y., Yang, D., Liang, Y., Yang, L., Hu, S., Liu, Z., Fang, Q., Tian, S., & Ding, Y. (2021) · Hepatology · doi:10.1002/hep.32068 · Cited by 85
The role of angiotensin II in nonalcoholic steatohepatitis
Morris, E. M., Fletcher, J. A., Thyfault, J. P., & Rector, R. S. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.04.013 · Cited by 81
Kahal, H., Abouda, G. F., Rigby, A. S., Coady, A., Kilpatrick, E. S., & Atkin, S. L. (2013) · Clinical Endocrinology · doi:10.1111/cen.12369 · Cited by 79
Nonalcoholic fatty liver disease and statins
Τζιόμαλος, Κ., Athyros, V. G., Paschos, P., & Karagiannis, A. I. (2015) · Metabolism · doi:10.1016/j.metabol.2015.07.003 · Cited by 81
Randomized Controlled Trial of a MUFA or Fiber-Rich Diet on Hepatic Fat in Prediabetes
Errazuriz, I., Dube, S., Slama, M. Q., VISENTIN, R., Nayar, S., O'Connor, H. T., Cobelli, C., Das, S. K., Basu, A., Kremers, W. K., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3722 · Cited by 79
Volynets, V., Machann, J., Küper, M. A., Maier, I. B., Spruss, A., Königsrainer, A., Bischoff, S. C., & Bergheim, I. (2012) · European Journal of Nutrition · doi:10.1007/s00394-012-0355-z · Cited by 76
George, E. S., Reddy, A., Nicoll, A. J., Ryan, M. C., Itsiopoulos, C., Abbott, G., Johnson, N. A., Sood, S., Roberts, S. K., & Tierney, A. C. (2022) · Liver International · doi:10.1111/liv.15264 · Cited by 76
Yari, Z., Cheraghpour, M., Alavian, S. M., Hedayati, M., Eini‐Zinab, H., & Hekmatdoost, A. (2020) · European Journal of Clinical Nutrition · doi:10.1038/s41430-020-0679-3 · Cited by 75
Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD)
Lombardi, R., Onali, S., Thorburn, D., Davidson, B. R., Gurusamy, K. S., & Tsochatzis, E. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011640.pub2 · Cited by 74
Lee, B., Lee, Y., Park, C., Rhee, E., Lee, W., Kim, N. H., Choi, K. M., Park, K., Choi, Y., Soo, B., et al. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0010 · Cited by 79
Biolato, M., Manca, F., Marrone, G., Cefalo, C., Racco, S., Miggiano, G. A. D., Valenza, V., Gasbarrini, A., Miele, L., & Grieco, A. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i4.509 · Cited by 78
Liu, J., Jiang, S., Zhao, Y., Sun, Q., Zhang, J., Shen, D., Wu, J., Shen, N., Fu, X., Sun, X., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5131 · Cited by 72
GLP-1 receptor agonists in NAFLD
Petit, J.-M., & Vergès, B. L. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30070-8 · Cited by 72
Protein and amino acids in nonalcoholic fatty liver disease
Tricò, D., Biancalana, E., & Solini, A. (2020) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000706 · Cited by 70
Dongiovanni, P., Paolini, E., Corsini, A., Sirtori, C. R., & Ruscica, M. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13519 · Cited by 73
Franco, I., Bianco, A., Mirizzi, A., Campanella, A., Bonfiglio, C., Sorino, P., Notarnicola, M., Tutino, V., Cozzolongo, R., Giannuzzi, V., et al. (2020) · Nutrients · doi:10.3390/nu13010066 · Cited by 73
Impaired LXRα Phosphorylation Attenuates Progression of Fatty Liver Disease
Bécares, N., Gage, M., Voisin, M., Shrestha, E., Martin‐Gutierrez, L., Liang, N., Louie, R., Pourcet, B., Pello, Ó. M., Luong, T. V., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.094 · Cited by 69
Aerobic exercise training in the treatment of non‐alcoholic fatty liver disease related fibrosis
Linden, M. A., Sheldon, R. D., Meers, G. M.-E., Ortinau, L. C., Morris, E. M., Booth, F. W., Kanaley, J. A., Vieira‐Potter, V. J., Sowers, J. R., Ibdah, J. A., et al. (2016) · The Journal of Physiology · doi:10.1113/jp272235 · Cited by 66
Established and emerging factors affecting the progression of nonalcoholic fatty liver disease
Kechagias, S., Nasr, P., Blomdahl, J., & Ekstedt, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154183 · Cited by 69
Hallsworth, K., Dombrowski, S. U., McPherson, S., Anstee, Q. M., & Avery, L. (2019) · Translational Behavioral Medicine · doi:10.1093/tbm/ibz080 · Cited by 67
Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis
Branković, M., Jovanović, I., Dukić, M., Radonjić, T., Oprić, S., Klašnja, S., & Zdravkovic, M. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095146 · Cited by 72
Musazadeh, V., Roshanravan, N., Dehghan, P., & Ahrabi, S. S. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.844242 · Cited by 69
Bhat, G. (2012) · World Journal of Hepatology · doi:10.4254/wjh.v4.i7.209 · Cited by 67
Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review
Arab, J. P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i34.12182 · Cited by 66
Oxidative stress and inflammation: liver responses and adaptations to acute and regular exercise
Barcelos, R. P., Royes, L. F. F., González‐Gallego, J., & Bresciani, G. (2017) · Free Radical Research · doi:10.1080/10715762.2017.1291942 · Cited by 66
Jańczyk, W., Socha, P., Lebensztejn, D. M., Wierzbicka, A., Mazur, A., Neuhoff-Murawska, J., & Matusik, P. (2013) · BMC Pediatrics · doi:10.1186/1471-2431-13-85 · Cited by 65
Hepatitis C therapy with HCV NS5B polymerase inhibitors
Soriano, V., Vispo, E., de Mendoza, C., Labarga, P., Fernández-Montero, J. V., Poveda, E., Treviño, A., & Barreiro, P. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.795543 · Cited by 63
NAFLD/NASH in patients with type 2 diabetes and related treatment options
Radaelli, M. G., Martucci, F., Perra, S., Accornero, S., Castoldi, G., Lattuada, G., Manzoni, G., & Perseghin, G. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0799-3 · Cited by 63
Exercising the hepatobiliary‐gut axis. The impact of physical activity performance
Molina‐Molina, E., Baccetto, R., Wang, D. Q. ‐., de Bari, O., Krawczyk, M. J., & Portincasa, P. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.12958 · Cited by 66
Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease?
Finelli, C. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i46.6790 · Cited by 63
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Reinson, T., Buchanan, R. M., & Byrne, C. D. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0348 · Cited by 69
Lanthier, N. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i19.2184 · Cited by 63
Avery, L., Exley, C., McPherson, S., Trenell, M. I., Anstee, Q. M., & Hallsworth, K. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.06.011 · Cited by 60
Mitochondria‐Mediated Pathogenesis and Therapeutics for Non‐Alcoholic Fatty Liver Disease
Li, Z., Li, Y., Zhang, H., Guo, J., Lam, C. W. K., Wang, C., & Zhang, W. (2019) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900043 · Cited by 64
Tutunchi, H., Ostadrahimi, A., Saghafi‐Asl, M., Hosseinzadeh‐Attar, M. J., Shakeri, A., Jafarabadi, M. A., Roshanravan, N., Farrin, N., Naemi, M., & Hasankhani, M. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104770 · Cited by 60
Zhu, Y., Xu, J., Zhang, D., Mu, X., Shi, Y. Y., Chen, S., Wu, Z., & Li, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.769069 · Cited by 59
Gamma-glutamyltransferase and risk of hypertension
Kunutsor, S. K., Apekey, T. A., & Cheung, B. M. Y. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000763 · Cited by 58
Strong and persistent effect on liver fat with a Paleolithic diet during a two-year intervention
Otten, J., Mellberg, C., Ryberg, M., Sandberg, S., Kullberg, J., Lindahl, B., Larsson, C. L., Hauksson, J. B., & Olsson, T. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.4 · Cited by 60
Gómez, E. V., Garcia, A. Y., Pérez, Y. M., Bertot, L. C., Gonzalez, A. T., Gra‐Oramas, B., Gonzalez‐Fabian, L., Villa-Jiménez, O. M., Friedman, S. L., Diago, M., et al. (2016) · Hepatology · doi:10.1002/hep.28484 · Cited by 63
Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus
Portillo-Sánchez, P., & Cusi, K. J. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0027-7 · Cited by 57
Role of diet on non-alcoholic fatty liver disease: An updated narrative review
Papandreou, D. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i3.575 · Cited by 55
A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis
McPherson, S., Wilkinson, N., TINIAKOS, D. G., Wilkinson, J. S., Burt, A. D., McColl, E., Stocken, D. D., Steen, N. D., Barnes, J. A., Goudie, N., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175717 · Cited by 55
Moosavian, S. P., Arab, A., & Paknahad, Z. (2019) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2019.10.008 · Cited by 56
Role of exercise-induced hepatokines in metabolic disorders
Ennequin, G., Sirvent, P., & Whitham, M. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00433.2018 · Cited by 54
Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
Kim, K., Lee, B., Kim, Y. J., Lee, D. H., Soo, B., & Park, C. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0034 · Cited by 55
Chai, X.-N., Zhou, B.-Q., Ning, N., Pan, T., Xu, F., He, S.-H., Chen, N.-N., & Sun, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1081096 · Cited by 52
Reversal of type 2 diabetes in youth who adhere to a very-low-energy diet: a pilot study
Gow, M. L., Baur, L. A., Johnson, N. A., Cowell, C. T., & Garnett, S. P. (2016) · Diabetologia · doi:10.1007/s00125-016-4163-5 · Cited by 53
Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review
Cazzo, E., Pareja, J. C., & Chaim, É. A. (2017) · Sao Paulo Medical Journal · doi:10.1590/1516-3180.2016.0306311216 · Cited by 54
Improving dietary patterns in patients with nonalcoholic fatty liver disease
Carvalhana, S. C., Machado, M. V., & Cortez‐Pinto, H. (2012) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e3283566614 · Cited by 52
Hallsworth, K., Avery, L., & Trenell, M. I. (2016) · Current Gastroenterology Reports · doi:10.1007/s11894-016-0485-1 · Cited by 52
Schwenger, K. J. P., Fischer, S. E., Jackson, T. D., Okrainec, A., & Allard, J. P. (2017) · Obesity Surgery · doi:10.1007/s11695-017-2980-3 · Cited by 51
Non-alcoholic fatty liver disease: What has changed in the treatment since the beginning?
Baran, B. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14219 · Cited by 51
Rifaximin in non‐alcoholic steatohepatitis: An open‐label pilot study
Cobbold, J., Atkinson, S. R., Marchesi, J. R., Smith, A., Wai, S. N., Stove, J., Shojaee‐Moradie, F., Jackson, N., Umpleby, A. M., Fitzpatrick, J. A., et al. (2017) · Hepatology Research · doi:10.1111/hepr.12904 · Cited by 50
Zhang, F., Zhang, Z., Kong, D., Zhang, X., Chen, L., Zhu, X., Lu, Y., & Zheng, S. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.09.020 · Cited by 50
Pioglitazone and vitamin E for nonalcoholic steatohepatitis: A cost utility analysis
Mahady, S. E., Wong, G., Craig, J. C., & George, J. (2012) · Hepatology · doi:10.1002/hep.25887 · Cited by 50
Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
Wijarnpreecha, K., Aby, E. S., Ahmed, A., & Kim, D. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0239 · Cited by 52
Schleicher, J., Guthke, R., Dahmen, U., Dirsch, O., Holzhütter, H., & Schuster, S. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.08.016 · Cited by 48
Inhibitory Effect of Gardenoside on Free Fatty Acid-Induced Steatosis in HepG2 Hepatocytes
Liang, H., Zhang, L., Wang, H., Tang, J., Yang, J., Chuncheng, W., & Chen, S. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161126058 · Cited by 48
Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD)
Carneros, D., López‐Lluch, G., & Bustos, M. (2020) · Nutrients · doi:10.3390/nu12113472 · Cited by 48
A critical evaluation of the role of iron overload in fatty liver disease
Fernandez, M., Lokan, J., Leung, C., & Grigg, A. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15971 · Cited by 46
Wang, Y., Zhou, Y., Wang, Z., Ni, Y., Prud’homme, G. J., & WANG, Q. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf336 · Cited by 52
Popov, V., & Lim, J. K. (2015) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2015.00019 · Cited by 45
Kunutsor, S. K., & Laukkanen, J. A. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.03.003 · Cited by 48
Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis
Buzzetti, E., Linden, A., Best, L. M., Madden, A. M., Roberts, D., Chase, T. J. G., Freeman, S. C., Cooper, N. J., Sutton, A. J., Fritche, D., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013156.pub2 · Cited by 46
Marchesini, G., Roden, M., & Vettor, R. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.11.002 · Cited by 46
Linden, M. A., Lopez, K. T., Fletcher, J. A., Morris, E. M., Meers, G. M.-E., Siddique, S., Laughlin, M. H., Sowers, J. R., Thyfault, J. P., Ibdah, J. A., et al. (2015) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2015-0236 · Cited by 45
Exercise as a therapeutic tool to prevent mitochondrial degeneration in nonalcoholic steatohepatitis
Gonçalves, I. O., Oliveira, P. J., Ascensão, A. A. M. R., & Magalhães, J. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12146 · Cited by 46
Ross, R., Soni, S., & Houle, S. (2020) · Nutrients · doi:10.3390/nu12040891 · Cited by 52
Effect of intragastric balloons on liver enzymes: A systematic review and meta-analysis
Popov, V. B., Thompson, C. C., Kumar, N., Ciarleglio, M. M., Deng, Y., & Laine, L. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4178-2 · Cited by 43
D’Adamo, E., Marcovecchio, M. L., Giannini, C., de Giorgis, T., Chiavaroli, V., Chiarelli, F., & Mohn, A. (2012) · Free Radical Research · doi:10.3109/10715762.2012.755262 · Cited by 44
Treatment of Non-Alcoholic Fatty Liver Disease
Dyson, J. K., & Day, C. (2014) · Digestive Diseases · doi:10.1159/000360511 · Cited by 43
Arslanow, A., Teutsch, M., Walle, H., Grünhage, F., Lammert, F., & Stokes, C. S. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.28 · Cited by 44
Musazadeh, V., Karimi, A., Malekahmadi, M., Ahrabi, S. S., & Dehghan, P. (2023) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13750 · Cited by 44
Scaglioni, F., Marino, M., Ciccia, S., Procaccini, A., Busacchi, M., Loria, P., Lonardo, A., Malavolti, M., Battistini, N., Pellegrini, M., et al. (2012) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2012.10.009 · Cited by 42
Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges
Xiao, J., Guo, R., Fung, M., Liong, E. C., & Tipoe, G. L. (2013) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(13)60021-1 · Cited by 44
Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease
Federico, A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i45.16841 · Cited by 43
Beneficial effects of the Mediterranean spices and aromas on non-alcoholic fatty liver disease
Baselga‐Escudero, L., Souza‐Mello, V., Pascual‐Serrano, A., Rachid, T. L., Voci, A., Demori, I., & Grasselli, E. (2017) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2016.11.019 · Cited by 42
Gut Microbiota at the Crossroad of Hepatic Oxidative Stress and MASLD
Termite, F., Archilei, S., D’Ambrosio, F., Petrucci, L., Viceconti, N., Iaccarino, R., Liguori, A., Gasbarrini, A., & Miele, L. (2025) · Antioxidants · doi:10.3390/antiox14010056 · Cited by 50
Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives
Clayton‐Chubb, D., Kemp, W. W., Majeed, A., Lubel, J. S., Hodge, A., & Roberts, S. K. (2023) · Nutrients · doi:10.3390/nu15030687 · Cited by 45
Ren, C., Gao, M.-Y., Li, N., Tang, C., Chu, G.-H., Yusuf, A., Xiao, L., Yang, Z., & Guan, T. (2024) · Food & medicine homology. · doi:10.26599/fmh.2024.9420015 · Cited by 45
The Association between Nonalcoholic Fatty Liver Disease and CT-Measured Skeletal Muscle Mass
Choe, E. K., Kang, H. Y., Park, B., Yang, J. I., & Kim, J. S. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7100310 · Cited by 41
Non-alcoholic fatty liver disease: A review with clinical and pathological correlation
Chen, Y., & Yeh, M. M. (2020) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2020.07.006 · Cited by 39
The Role of Lifestyle Change in the Prevention and Treatment of NAFLD
Centis, E., Marzocchi, R., Suppini, A., Grave, R., Villanova, N., Hickman, I. J., & Marchesini, G. (2012) · Current Pharmaceutical Design · doi:10.2174/1381612811319290008 · Cited by 40
Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis
Ratziu, V., Ghabril, M., Romero‐Gómez, M., & Svegliati‐Baroni, G. (2018) · Transplantation · doi:10.1097/tp.0000000000002483 · Cited by 40
Recenti, M., Ricciardi, C., Edmunds, K. J., Gíslason, M. K., Sigurdsson, S. O., Carraro, U., & Gargiulo, P. (2020) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2020.3044158 · Cited by 38
MetALD: Does it require a different therapeutic option?
Marek, G. W., & Malhi, H. (2024) · Hepatology · doi:10.1097/hep.0000000000000935 · Cited by 41
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 44
Cobbold, J., Patel, D., & Taylor-Robinson, S. D. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2012.07127.x · Cited by 37
Farhangi, M. A., Dehghan, P., Musazadeh, V., Kavyani, M., & Maleki, P. (2022) · Journal of Functional Foods · doi:10.1016/j.jff.2022.105074 · Cited by 37
Non-alcoholic fatty liver disease in children now: Lifestyle changes and pharmacologic treatments
Alisi, A., & Nobili, V. (2012) · Nutrition · doi:10.1016/j.nut.2011.11.017 · Cited by 36
Management of Nonalcoholic Steatohepatitis
Mahady, S. E., & George, J. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.05.003 · Cited by 36
Metadata
- Authors
- Thoma, C., Day, C. P., & Trenell, M. I.
- Affiliations
- Newcastle University (GB)
- Corresponding author
- Trenell, Michael I.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2012-01
- Volume
- 56
- Issue
- 1
- Pages
- 255-266
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2010662354
- Cited by
- 523
- References
- 53
- Citations by year
- 2026: 14 · 2025: 17 · 2024: 30 · 2023: 37 · 2022: 35 · 2021: 43 · 2020: 42 · 2019: 36 · 2018: 32 · 2017: 46 · 2016: 46 · 2015: 46 · 2014: 40 · 2013: 32 · 2012: 23
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Hepatology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- National Institute for Health and Care Research (SRF-2011-04-017)
- Medical Research Council (MC_G0802536)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, lifestyle intervention, dietary intervention, physical activity, weight loss, liver fat, hepatic steatosis, liver fibrosis, liver inflammation, insulin sensitivity, glycemic control, transaminases
- MeSH terms
- Adult, Aged, Clinical Trials as Topic, Combined Modality Therapy, Diet Therapy, Exercise Therapy, Fatty Liver, Female, Humans, Life Style, Male, Middle Aged, Motor Activity, Prospective Studies, Lipid Metabolism, Weight Reduction Programs, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
